{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-05T21:04:33.010719+00:00","company":{"ticker":"AMLX","cik":1658551,"company_name":"Amylyx Pharmaceuticals, Inc."},"pagination":{"limit":100,"returned":6,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"f79ed0d06ead6cc7700bdd90f9c52a559602d919","cik":1658551,"ticker":"AMLX","company_name":"Amylyx Pharmaceuticals, Inc.","filed_at":"2026-05-07T23:59:59+00:00","payload":{"eps_text":"$0.37 per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss for the three months ended March 31, 2026 was $41.3 million, or $0.37 per share","period_text":"first quarter ended March 31, 2026","report_date":"2026-05-07","result_type":"reported_results","revenue_text":null},"claim":"Amylyx Pharmaceuticals, Inc. reported first quarter ended March 31, 2026 results: net income Net loss for the three months ended March 31, 2026 was $41.3 million, or $0.37 per share, EPS $0.37 per share.","evidence_excerpt":"Net loss for the three months ended March 31, 2026 was $41.3 million, or $0.37 per share, compared to net loss of $35.9 million, or $0.42 per share, for the same period in 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-210286","anchor_url":"https://secwatch.observer/filing/0001193125-26-210286#claim-f79ed0d06ead6cc7700bdd90f9c52a559602d919","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526210286/0001193125-26-210286-index.htm"},{"fact_type":"earnings_release","fact_key":"aee4b330212c681ed5bdb3405187bab311607e6e","cik":1658551,"ticker":"AMLX","company_name":"Amylyx Pharmaceuticals, Inc.","filed_at":"2024-05-09T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"first quarter ended March 31, 2024","report_date":"2024-05-09","result_type":"reported_results","revenue_text":null},"claim":"Amylyx Pharmaceuticals, Inc. reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"On May 9, 2024, Amylyx Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended March 31, 2024.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-056254","anchor_url":"https://secwatch.observer/filing/0000950170-24-056254#claim-aee4b330212c681ed5bdb3405187bab311607e6e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017024056254/0000950170-24-056254-index.htm"},{"fact_type":"restructuring_charge","fact_key":"7ccf6a8096b711a3d221bb0cfe2bc6aae713bbb0","cik":1658551,"ticker":"AMLX","company_name":"Amylyx Pharmaceuticals, Inc.","filed_at":"2024-04-04T23:59:59+00:00","payload":{"affected_area":"not specified","charge_text":"approximately $19 million","effective_date":"2024-04-03","event_type":"restructuring","headcount_text":"approximately 70%","item_codes_triggered":["2.05","2.06"]},"claim":"Amylyx Pharmaceuticals, Inc. announced a restructuring with charges of approximately $19 million affecting not specified (approximately 70%).","evidence_excerpt":"Plan by the end of the third quarter of 2024. As part of this Restructuring Plan, the Company expects to incur severance and severance-related charges of approximately $19 million. The Company is also evaluating its inventory purchase commitments and the impact its Restructuring Plan will have on inventory obsolescence. The Company may also incur other","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-24-086609","anchor_url":"https://secwatch.observer/filing/0001193125-24-086609#claim-7ccf6a8096b711a3d221bb0cfe2bc6aae713bbb0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312524086609/0001193125-24-086609-index.htm"},{"fact_type":"executive_change","fact_key":"9a5a337ead","cik":1658551,"ticker":"AMLX","company_name":"Amylyx Pharmaceuticals, Inc.","filed_at":"2024-03-14T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-03-14","interim":false,"role":"Class I Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Bernhardt Zeiher was appointed as Class I Director at Amylyx Pharmaceuticals, Inc..","evidence_excerpt":"On March 14, 2024 (the “Effective Date”), the Board of Directors (the “Board”) of Amylyx Pharmaceuticals, Inc. (the “Company”) appointed Bernhardt Zeiher, MD, FCCP, FACP to fill a vacancy on the Board as a Class I director","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-067471","anchor_url":"https://secwatch.observer/filing/0001193125-24-067471#claim-9a5a337ead","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312524067471/0001193125-24-067471-index.htm"},{"fact_type":"earnings_release","fact_key":"c1b80cf4ac4f490d68041283ab08e389b4ec5a6d","cik":1658551,"ticker":"AMLX","company_name":"Amylyx Pharmaceuticals, Inc.","filed_at":"2024-02-22T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$49.3 million","period_text":"the fiscal year ended December 31, 2023","report_date":"2024-02-22","result_type":"reported_results","revenue_text":"$380.8 million"},"claim":"Amylyx Pharmaceuticals, Inc. reported the fiscal year ended December 31, 2023 results: revenue $380.8 million, net income $49.3 million.","evidence_excerpt":"• Reported $380.8 million in net product revenue for the full year 2023, including $108.4 million in the fourth quarter • Delivered $49.3 million in net income for the full year 2023, including $4.7 million in the fourth quarter","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-018409","anchor_url":"https://secwatch.observer/filing/0000950170-24-018409#claim-c1b80cf4ac4f490d68041283ab08e389b4ec5a6d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017024018409/0000950170-24-018409-index.htm"},{"fact_type":"earnings_release","fact_key":"9cdd4702e1091d230a4be0ecaff7917eb01810d5","cik":1658551,"ticker":"AMLX","company_name":"Amylyx Pharmaceuticals, Inc.","filed_at":"2024-02-22T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$4.7 million","period_text":"the fourth quarter ended December 31, 2023","report_date":"2024-02-22","result_type":"reported_results","revenue_text":"$108.4 million"},"claim":"Amylyx Pharmaceuticals, Inc. reported the fourth quarter ended December 31, 2023 results: revenue $108.4 million, net income $4.7 million.","evidence_excerpt":"• Reported $380.8 million in net product revenue for the full year 2023, including $108.4 million in the fourth quarter • Delivered $49.3 million in net income for the full year 2023, including $4.7 million in the fourth quarter","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-018409","anchor_url":"https://secwatch.observer/filing/0000950170-24-018409#claim-9cdd4702e1091d230a4be0ecaff7917eb01810d5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017024018409/0000950170-24-018409-index.htm"}]}